Follicular fluid levels of vascular endothelial growth factor and early corpus luteum function during assisted reproductive technology cycles by Coppola, F et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Journal of Experimental & Clinical 
Assisted Reproduction
Open Access Research
Follicular fluid levels of vascular endothelial growth factor and early 
corpus luteum function during assisted reproductive technology 
cycles
F Coppola*, B Ferrari, L Barusi, V Caccavari, MC Salvarani and G Piantelli
Address: Center for Reproductive Medicine – Department of Obstetrics, Gynecology and Neonatology – University of Parma – 43100 Parma – Italy
Email: F Coppola* - francesco.coppola@unipr.it; B Ferrari - bruno.ferrari@unipr.it; L Barusi - lobarusi@tin.it; 
V Caccavari - vcaccavari@yahoo.it; MC Salvarani - mariacristina.salvarani@unipr.it; G Piantelli - giovanni.piantelli@unipr.it
* Corresponding author    
Abstract
Background: The relation between vascular endothelial growth factor (VEGF) and early luteal
function has rarely been proven in humans. The purpose of this study was to define the relation
between follicular fluid concentrations of VEGF (FF VEGF) and early luteal function at the
preimplantation stage during assisted reproductive technology (ART) cycles.
Methods: 71 women were divided into two groups, based on reproductive outcome: women who
became pregnant after embryo transfer (ET) (n = 18, Group A) and non-pregnant women (n = 53,
Group B). Serum progesterone (Se P) and inhibin A on ET day, and FF VEGF levels were measured
in all women. Data were expressed as mean ± standard deviation. Statistical analysis was performed
using Excel Office 98 for Student's t-test, linear regression test and chi-square test. A p value of <
0.05 was considered statistically significant.
Results: The groups were comparable for age, ovarian reserve, number and quality of the oocytes
retrieved and of the embryos obtained and transferred. FF VEGF levels were increased (4235 ±
1433 vs 3432 ± 1231 pg/ml), while Se P and inhibin A levels were significantly reduced (83.1 ± 34.1
vs 112.0 ± 58.8 ng/ml and 397.4 ± 223 vs 533.5 ± 283 pg/ml, respectively) in the non-pregnant group
and were negatively correlated with FF VEGF (r = -0.482, p < 0.05; r = -0.468, p < 0.05) only in
pregnant women.
Conclusion: Much has to be learned about the regulation and role of VEGF during the early luteal
phase. We advance the hypothesis that the existence of a negative correlation between FF VEGF/
Se P and FF VEGF/inhibin A in pregnant women might indicate the existence of a normal VEGF-
mediated paracrine response when Se P and inhibin A levels are decreased. Excess production of
FF VEGF and the absence of a correlation between FF VEGF/Se P and FF VEGF/inhibin A in non-
pregnant women may be a paracrine reaction to immature luteal vasculature, resulting in luteal
dysfunction.
Background
Several aspects of reproduction, from folliculogenesis to
corpus luteum function, from embryo implantation to
placental function, are related to angiogenesis [1-3]. The
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relation between vascular endothelial growth factor
(VEGF) and luteal vascularization has been demonstrated
in a large number of studies on animals [1-3], but it has
rarely been proven in humans [4] and during assisted
reproductive technology (ART) cycles [5]. This growth fac-
tor, which is produced by granulosa and thecal cells in
response to FSH, LH and hCG production, and to
hypoxia, is a potent angiogenic cytokine. It plays a prom-
inent role in the development of an extensive, mature vas-
cular network around the follicles and within the corpus
luteum [4]. In a group of 13 women undergoing ART and
regardless of reproductive outcome, Lee A. et al. [5] found
that VEGF concentration in the follicular fluid (FF VEGF)
at the time of oocyte retrieval (day 0) was positively corre-
lated with serum (Se P) and follicular fluid (FF P) proges-
terone. This in turn indicates a correlation between FF
VEGF and follicular luteinization at a very early stage, in a
process that can be described as the first wave of angiogen-
esis. At 11 to 14 days after ET (day +11 to +13), the same
authors [5] reported that the pregnant recipients of autol-
ogous fresh embryos had higher serum VEGF levels than
both non-pregnant recipients of autologous fresh
embryos and pregnant recipients of donor eggs. These
data suggest that at onset of gestation, endogenous hCG
produced by the embryo stimulates ovarian VEGF produc-
tion, a process also known as the second wave of
angiogenesis.
The purpose of this study was to define the relation
between FF VEGF levels and early luteal function at the
preimplantation stage – 3 days after oocyte retrieval (day
+3), before endogenous hCG produced by the embryo
stimulates ovarian VEGF production – and to verify
whether dysfunction in VEGF production may interfere
with luteal function during ART.
Methods
Patients
The study was performed on follicular fluid and blood
samples routinely collected on oocyte pick-up day and 3
days after oocyte retrieval, respectively, in 71 infertile
women referred for IVF-ET to the Center for Reproductive
Medicine of the University of Parma Department of
Obstetrics, Gynecology and Neonatology between Sep-
tember 2002 and March 2003. Inclusion criteria were:
normogonadotropic women regularly menstruating with
normal ovulatory function and normal corpus luteum
processes, age under 40, and baseline FSH levels lower
than 10 IU/L. Exclusion criteria were: genital conditions
that might interfere with implantation, e.g. fibroma, hyd-
rosalpinx, uterine malformations, polycystic ovary
(PCO), endometriosis, and such complications as ovarian
hyperstimulation syndrome (OHSS), chemical or clinical
abortion. The patients were divided into two groups,
based on reproductive outcome following ART: ongoing
pregnancy after ET (Group A, n = 18) and non-pregnancy
(Group B, n = 53). Permission for use of the follicular
fluid and blood samples for this study was given by the
University of Parma Ethics Committee. All patients gave
their informed consent to IVF-ET.
Stimulation protocol
All patients underwent controlled ovarian hyperstimula-
tion (COH) following pituitary desensitization with a
GnRH agonist (leuprolide 0.5 mg/day s.c. by Takeda Italia
Farmaceutici, Rome, Italy) administered on day 21 of the
cycle. The women were first monitored for inhibition of
all ovarian activity and then stimulated with a standard
dose of 225 IU of recombinant FSH (rFSH) (Gonal F 75
by Serono, Rome, Italy). The dose was later adjusted
according to each patient's response. Ovarian response
was monitored by serum estradiol (Se E2) assay and trans-
vaginal sonography every other day. Finally, the patients
received a dose of 10,000 IU of hCG (Profasi HP by
Serono, Rome, Italy) when at least two follicles were > 16
mm and Se E2 levels were > 1000 pg/ml. The thickness of
the endometrium was assessed by transvaginal sonogra-
phy on the day of hCG administration.
Oocyte retrieval and ET
Oocytes were retrieved for IVF 35 hours after hCG admin-
istration by transvaginal ultrasound-guided aspiration.
The oocytes thus obtained were tested in the laboratory
and classified into four maturation stages depending on
the maturity of the oocyte-cumulus-corona complex. For
the purpose of this study, oocytes were considered mature
when they showed an extensive dispersal of the investing
granulosa cells and an expanded cumulus and corona,
while the zona pellucida was distinct and the ooplasm
clear (Type 1). Oocytes of intermediate maturity mani-
Table 1: Patient population characteristics.
Group A Group B p
Cases (no.) 18 53
Age (M ± SD) 33.9 ± 3.6 34.0 ± 3.13 n.s.
Baseline Se FSH (IU/L) (M ± SD) 7.1 ± 2.4 6.8 ± 2.5 n.s.
Se LH, day +6 (IU/L) (M ± SD) 1.2 ± 1.0 1.3 ± 1.1 n.s.
Se E2, hCG day (pg/ml) (M ± SD) 1401 ± 597 1467 ± 716 n.s.
rFSH (IU/pt) (M ± SD) 3098 ± 949 3562 ± 1256 n.s.Journal of Experimental & Clinical Assisted Reproduction 2005, 2:13 http://www.jexpclinassistreprod.com/content/2/1/13
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fested a slightly denser corona and a dispersed cumulus,
and lacked a nuclear membrane (Type 2). Immature
oocytes were surrounded by a compact corona and few
cell layers in the cumulus (Type 3). Atretic or postmature
oocytes displayed a dark, irregular ooplasm (Type 4).
Embryos were classified according to the criteria proposed
in 1994 by C. Staessen et al. [6]: Type 1, or excellent
embryos (blastomers of equal size or, if not of equal size,
without anucleate fragments); Type 2, or good embryos
(blastomers of equal size or, if not of equal size, with up
to 20% the volume of the embryo filled with anucleate
fragments); and, Type 3, or fair embryos (anucleate frag-
ments present in 20–50% the volume of the embryo). ET
was performed 3 days after oocyte retrieval (110 hours
after hCG administration). ET was considered difficult
when there was blood on the catheter after transfer. The
luteal phase was supported with 200 mg micronized pro-
gesterone (Esolut by Angelini S.p.A, Rome, Italy) admin-
istered daily (100 mg in the morning and 100 mg in the
evening) by vaginal route, starting on the day of oocyte
pick-up and continuing until the day of the pregnancy
test.
Pregnancy was considered ongoing if serum levels of beta
hCG (Se βhCG) at day 16 after oocyte pick-up were above
112 mIU/mL (10th percentile of our trend curve) and con-
firmed by ultrasound at day 35 after oocyte pick-up.
Follicular fluid and blood sampling and assays
The patients' blood samples were tested: i) on day 3 of the
cycle, 3 to 6 months prior to ovarian stimulation (baseline
FSH); ii) on day 6 of ovarian stimulation (Se LH); iii) on
hCG day (Se E2); and, iv) on ET day (Se P and inhibin A).
Se E2 (pg/ml) and Se P (ng/ml) levels were determined in
duplicate using a chemoluminescence kit (Medical Sys-
tem, Genoa, Italy). Se FSH (IU/L) and Se LH
(IU/L) were determined in duplicate by chemolumines-
cence using Coat-A-Count FSH and LH IRMA kits (manu-
factured by Euro/Diagnostic Products Corporation,
Witney, Oxfordshire, UK).
Inhibin A measurement (pg/ml) was performed by solid-
phase sandwich enzyme-linked immunosorbant assay
(ELISA) using a DSL kit manufactured by Webster, Texas,
USA, and distributed by Pantec, Turin, Italy.
Inhibin A reflects ovarian function and is a product not
only of the fetoplacental unit but also of the corpus
luteum in early pregnancy [7-11]. It would then represent
a more reliable index of corpus luteum function than Se P
in women concomitantly receiving vaginal micronized
progesterone [7].
The follicular fluid pool from each patient was centrifuged
at 900 g/min for 15 minutes to remove cellular and blood
contamination and then kept at -70°C for the subsequent
determination in duplicate of FF VEGF. The assay tech-
nique used in this study was: ELISA for total FF VEGF (pg/
ml) (R&D System, Minneapolis, Minnesota, USA).
Intra- and interassay parameter variations were 4% and
4.2% for E2, 2.2% and 4% for FSH, 1% and 2.2% for LH,
6.2% and 6.7% for progesterone, 6.0% and 7.4% for
inhibin A, respectively, and < 8% for VEGF.
Statistical analysis
Data were expressed as mean (M) ± standard deviation
(SD). Statistical analysis was performed using Excel Office
98 for Student's t-test, linear regression test and chi-square
test. A p value of < 0.05 was considered statistically
significant.
Results
The characteristics of the patients under study – number,
age, ovarian reserve, as well as Se LH levels on day 6 of
ovarian stimulation (+6), and Se E2 levels on hCG day –
are reported in Table 1.
As no significant differences emerged between women
who became pregnant after ET (Group A) and non-preg-
nant women (Group B), the two groups could be consid-
ered comparable in view to the examined parameters. A
comparison of data for the IVF-ET procedure in the two
Table 2: IVF-ET data. Values are given as M ± SD
Group A Group B p
Total oocytes/pt 8.4 ± 4.0 8.1 ± 4.3 n.s.
Oocytes type 1,1–2/pt 7.9 ± 3.6 7.0 ± 4.2 n.s.
Total embryos/pt 4.2 ± 2.0 3.7 ± 1.8 n.s.
Embryo type 1/pt 2.6 ± 1.8 2.0 ± 1.9 n.s.
Endometrial thickness (mm) 11.1 ± 2.9 10.9 ± 2.7 n.s.
Embryos transferred/pt 3.1 ± 0.8 3.0 ± 1.0 n.s.
Difficult ET (no./%) 1/18 5,5% 2/53 3,7% n.s.Journal of Experimental & Clinical Assisted Reproduction 2005, 2:13 http://www.jexpclinassistreprod.com/content/2/1/13
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groups (Table 2) did not show any differences in the
number and quality of the oocytes retrieved, in the
embryos obtained and transferred in utero and in difficult
ET. Measurement of endometrial thickness did not differ
in the two groups, either (Table 2).
FF VEGF levels – an expression of the follicular paracrine
environment – were significantly elevated (p = 0.039) in
non-pregnant women (4235 pg/ml ± 1443) compared
with women who became pregnant after ET (3432 pg/ml
± 1231) (Table 3).
Se P and inhibin A levels measured in the early luteal
phase were significantly (p = 0.013 and p = 0.04) elevated
in Group A (112.0 ng/ml ± 58.8 and 533.5 pg/ml ± 283)
versus Group B (83.1 ng/ml ± 34.1 and 397.4 pg/ml ±
223) (Table 3) and were negatively correlated with FF
VEGF (r = -0.482, p < 0.05; r = -0.468, p < 0.05) only in
Group A; no correlation (r = -0.179, p n.s.; r = -0.09, p n.s.)
was found in Group B (Table 3). Despite the concomitant
administration of vaginal micronized progesterone, Se P
was well correlated (r = 0.646, p < 0.001) with inhibin A
(Fig 1). This reduced the degree of inaccuracy that Se P
might exhibit versus inhibin A in luteal function
expression.
Discussion
In our study, the two patient groups were comparable, not
only for clinical characteristics, but also for the number
and quality of the oocytes retrieved and of the embryos
obtained and transferred in each group. Se P and inhibin
A levels were significantly (p = 0.013 and p = 0.042) more
elevated in pregnant women versus women who failed to
conceive, while the angiogenic reaction was more marked
(p = 0.03) in the latter. The cause of this excess angiogenic
reaction is not yet clear. Under normal conditions, hCG
administered to trigger ovulation induces the formation
of a vascular network (first wave of angiogenesis) that
helps ensure the correct development and functioning of
the corpus luteum as a primary source of circulating pro-
gesterone [12] and inhibin A. In our study, the existence
of a negative correlation (r = -0.482 and r = -0.468, p <
0.05) between FF VEGF/Se P and FF VEGF/inhibin A in
pregnant women enabled us to demonstrate the existence
of a normal VEGF-mediated paracrine reaction when Se P
and inhibin A levels were decreased.
Beyond a given limit, as is the case with non-pregnant
patients in whom there is no such correlation (r = -0.178
and r = -0.092, p n.s.), excess VEGF production is no
longer enough to induce the formation of a mature vascu-
lar network in the corpus luteum through a paracrine
mechanism and consequently to sustain adequate pro-
duction of progesterone and inhibin A. This is also con-
firmed by studies on animals [13,1,14], revealing that
luteal function can be impaired by anti-VEGF treatments
down to a 50% reduction in Se P concentrations [2]. A
large part of endothelial cells in the vascular network of
the corpus luteum depend on VEGF support. Several vari-
ables, such as oxygen tension [15,16], insulin-like growth
factor [3], aging [15], and poor response to ovarian stim-
ulation [17], modulate the expression of this angiogenic
factor. The pre-ovulatory follicle is a relatively large avas-
cular multicellular structure [18]. Using mathematical for-
mulas, it has been calculated that O2 content is potentially
Table 3: Follicular environment and luteal function. Values are given as M ± SD
Group A Group B p
FF VEGF (pg/ml) 3432 ± 1231 4235 ± 1443 0.039
Se P (ng/ml) 112.0 ± 58.8 83.1 ± 34.1 0.013
Inhibin A (pg/ml) 533.5 ± 283 397.4 ± 223 0.042
FF VEGF vs Se P r = -0.482 (a) r = -0.178 (b) (a) < 0.05; (b) n.s.
FF VEGF vs inhibin A r = -0.468 (c) r = -0.092 (d) (c) < 0.05; (d) n.s.
(a) and (b) are correlation coefficients of FF VEGF to FF P
(c) and (d) are correlation coefficients of FF VEGF to inhibin A
Correlation between Se P and inhibin A Figure 1
Correlation between Se P and inhibin A.
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below the normal-range threshold (underoxygenation)
[19], since the amount of O2 within mature follicles has
been documented to range from less than 1% to about
5.5% [20]. Luteal expression of VEGF occurs primarily in
specific perivascular cells, including arteriolar smooth
muscle and capillary pericytes, and is regulated primarily
by oxygen levels [12].
The reduced effect of exogenous hCG given to trigger ovu-
lation on follicular luteinization in the women who failed
to conceive and the consequent failure to achieve preg-
nancy in spite of supplemental progesterone administra-
tion in the luteal phase raises the question of whether
exogenous hCG is capable of sustaining an adequate cor-
pus luteum vascularization and whether progesterone can
effectively substitute for luteal function. Our data seem to
indicate that luteal function before ET is improved only in
women who become pregnant. This might be due not
only to improved corpus luteum vascularization, but also
to a consequently adequate production of other local fac-
tors [21] of luteal origin (inhibin, oxitocin, growth factor,
cytokines, prostaglandins and leucotrienes), which act in
an autocrine or paracrine manner to modulate and per-
haps mediate the development and function of the corpus
luteum. Further studies are needed to investigate this
aspect and lead to an in-depth understanding of the cor-
pus luteum regulation mechanisms. The achievement of
pregnancy following ART depends on a variety of factors
(immunologic, genetic as well as endocrine, paracrine and
vascular). In particular, getting to know with certainty
why a woman fails to conceive is a crucial part of the proc-
ess. Based on our study that evaluated only the maternal
side prior to implantation in a selected sample of patients,
we can hypothesize that suboptimal early luteal function
– a condition related to immature vasculature – may play
an important role in ART failure.
Conclusion
Much has to be learned about the regulation and role of
VEGF during the final stage of follicular development and
the early luteal phase. We advance the hypothesis that the
negative correlation between FF VEGF and the early luteal
phase in pregnant women and elevated FF VEGF levels in
non-pregnant women could be ascribed to a paracrine
response compensating for perifollicular hypoxia and that
luteal malfunction in women that fail to conceive could
be the expression of an immature luteal vasculature. This
mechanism is likely to occur when there is not enough
angiogenic compensation and represents a clinical appli-
cation of what has already been found in tests on non-
human primates. However, further studies are needed to
determine the role played by angiogenic factors or other
substances, such as recombinant hCG, in controlling the
growth and maturation of perifollicular and luteal vascu-
lature, in order to find new therapeutic strategies that may
help treat sterility by manipulating angiogenesis.
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